A Randomized Phase II Trial of First-Line Treatment with Gemcitabine, Erlotinib, or Gemcitabine and Erlotinib in Elderly Patients (Age (cid:1) 70 Years) with Stage IIIB/IV Non-small Cell Lung Cancer